Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients

Journal of Heart and Lung Transplantation

Volumn 20, Issue 6, 2001, Pages 611-618

  Penson, Matthew G ^a   Fricker, F Jay ^a   Thompson, Jeffrey R ^a   Harker, Kelli ^b   Williams, Barbara J ^b   Kahler, Deborah A ^c   Schowengerdt, Kenneth O ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Shands Cancer Center   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AZATHIOPRINE; CHOLESTEROL; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPID; LIVER ENZYME; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRAVASTATIN; PREDNISONE; TACROLIMUS; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LIPID BLOOD LEVEL; MALE; MYOSITIS; PATIENT; PRIORITY JOURNAL; RECIPIENT; RISK FACTOR; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIPIDS; MALE; PRAVASTATIN; RETROSPECTIVE STUDIES; TACROLIMUS; TRANSAMINASES;

EID: 0034987016     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(01)00251-0     Document Type: Article

References (25)

1. Decreasing incidence of coronary disease in pediatric cardiac transplant recipients using increased immunosuppression
2. Hypercholesterolemia in long-term survivors of heart transplantation; an early marker of accelerated coronary artery disease
3. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia
4. Effects of cyclosporine therapy on plasma lipoprotein levels
5. Hyperlipidemia after heart transplantation
6. Hyperlipidemia after clinical heart transplantation
7. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients
8. Hypercholesterolemia after cardiac transplantation in children
9. Frequency of hypercholesterolemia after cardiac transplantation
10. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation
11. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients
12. Tissue selectivity of hydroxymethylglutarl coenzyme A (HMG CoA) reductase inhibitors
13. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients; are the statins mechanistically similar?
14. Effect of pravastatin on outcomes after cardiac transplantation
15. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation
16. Pathophysiology and treatment of lipid perturbation after cardiac transplantation
17. Increased lipid peroxidation in cyclosporine-treated heart transplant recipients
18. Effects of pravastatin on chronic rejection of rat cardiac allografts
19. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors; simvastatin and pravastatin
20. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease
21. Toxicity of the HMG-CoA reductase inhibitor lovastatin to rabbits
22. Cholesterol-lowering therapy after heart transplantation; a 12-month randomized trial
23. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia
24. Statins after cardiac transplantation; which statin, what dose, and how low should we go?